Semaglutide at a Med Spa or Weight Loss Clinic: What It Is, Cost and Who Prescribes

Semaglutide is a GLP-1 receptor agonist, a drug that acts on the GLP-1 receptor.

Tirzepatide, a related drug, acts on both the GIP and the GLP-1 receptors; semaglutide acts on the GLP-1 receptor only.

The same active ingredient is sold under more than one brand name, with different FDA approvals — which is where much of the confusion around this drug starts.

Wegovy (semaglutide, Novo Nordisk) injection is FDA-approved, with diet and activity, to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight; to reduce and maintain weight loss long term in adults and children 12 years and older with obesity and in adults with overweight plus at least one weight-related condition; and, under accelerated approval, for noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3) in adults.

Since a December 2025 label update, Wegovy has also come as an oral tablet, taken at a maintenance dose of 25 mg once daily and approved for weight reduction and cardiovascular risk reduction in adults; the tablet form is for adults only, and the pediatric indication is injection only.

Ozempic is also semaglutide, but it is FDA-approved for type 2 diabetes — glycemic control, cardiovascular risk reduction, and reduced risk of kidney outcomes in type 2 diabetes with chronic kidney disease — and it is not FDA-approved for weight loss.

Using Ozempic for weight loss is off-label: that use is not on any current US label for the product.

As an injection, Wegovy is taken once weekly, and the label raises the dose in steps: 0.25 mg weekly for weeks 1–4, 0.5 mg for weeks 5–8, 1 mg for weeks 9–12 and 1.7 mg for weeks 13–16, reaching the recommended maintenance dose of 2.4 mg at week 17; 1.7 mg weekly is an alternative adult maintenance dose.

The label also allows a higher maximum dose, Wegovy HD 7.2 mg once weekly, for adults who have tolerated 2.4 mg for at least 4 weeks when more weight reduction is clinically indicated.

The tablet titrates in 30-day steps — 1.5 mg, then 4 mg, then 9 mg — before reaching the 25 mg once-daily maintenance dose on day 91.

Wegovy's weight-reduction indication covers adults and children 12 years and older with obesity, and adults with overweight who have at least one weight-related condition.

Those are the populations the label was approved for; whether a GLP-1 is appropriate for you is a decision for a licensed prescriber who has evaluated your health history.

At a med spa or weight loss clinic, semaglutide can only reach you by prescription: a licensed prescriber must evaluate you and write the prescription, and FDA tells patients to fill prescriptions at state-licensed pharmacies.

The label also names people the drug should not be used in.

Wegovy is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

The label says to stop Wegovy when pregnancy is recognized, and to discontinue it at least 2 months before a planned pregnancy because of semaglutide's long half-life; breastfeeding is not recommended while taking Wegovy tablets.

Beyond those label statements we will not give you a yes-or-no checklist: screening is individual, so a licensed prescriber needs to evaluate your health history before any decision about this drug.

The other option you may encounter at a med spa or clinic is compounded semaglutide — semaglutide made by a compounding pharmacy rather than the brand manufacturer.

Compounded drugs are not FDA-approved: FDA does not review them for safety, effectiveness or quality before they are sold, and the agency says compounded drugs should be used only in patients whose medical needs cannot be met by an FDA-approved drug.

FDA lists "the compounded drug is the same as an FDA-approved drug" among the claims it calls red flags, so a program marketing its compounded semaglutide as identical to, a generic of, or an equivalent to Wegovy or Ozempic is naming exactly what FDA warns about.

The shortage rationale for compounding is gone: FDA declared the semaglutide injection shortage resolved on February 21, 2025 — it had been in shortage since 2022 — and gave 503A pharmacies until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 to stop making essentially-copy products.

Compounding has not been banned outright, either: under FDA's 503A rules, a copy of an approved drug remains possible for an individual patient when the prescriber determines and documents that a change in the drug produces a significant clinical difference for that patient.

Two FDA specifics matter when you evaluate an offer: adding another ingredient, such as vitamin B12, does not automatically take a product outside the "essentially a copy" rule, and FDA says it is not aware of any lawful basis for compounding with semaglutide salt forms (semaglutide sodium or semaglutide acetate), which are different active ingredients from the ones in approved drugs.

FDA has also warned companies selling semaglutide products falsely labeled "for research purposes" or "not for human consumption," and urges consumers not to buy them.

As of May 31, 2026, FDA had received 990 adverse-event reports associated with compounded semaglutide — a count the agency notes is likely underreported, because 503A pharmacies are not required to report adverse events.

The trial behind the headline numbers is STEP 1 (Wilding et al., NEJM 2021), in adults with overweight or obesity who did not have diabetes: the mean body-weight change at 68 weeks was -14.9% with semaglutide 2.4 mg (-15.3 kg) versus -2.4% (-2.6 kg) with placebo.

In the same trial, 86.4% of participants on semaglutide lost at least 5% of their body weight and 50.5% lost at least 15%; the trial included a lifestyle intervention alongside the drug.

Results are smaller in people with type 2 diabetes: in STEP 2 (the Wegovy label's Study 3), mean weight change at 68 weeks was -9.6% with semaglutide versus -3.4% on placebo.

The tablet form has trial data of its own: in the Wegovy label's Study 7, the 25 mg tablet produced a -13.6% mean weight change over 64 weeks, versus -2.4% on placebo.

On speed: the label's dose escalation alone takes 16 weeks, and STEP 1 measured results at week 68, so the headline numbers describe more than a year of treatment.

No label or trial text we read gives month-by-month weight-loss figures in words — the labels show weight over time only in charts — and weight loss accrued gradually over the 64- to 68-week trials, so a program promising a specific loss by a specific month is going beyond what those sources state.

What happens when the drug stops is part of the results picture.

In STEP 4 (Rubino et al., JAMA 2021, 803 participants), after a 20-week run-in on semaglutide with a mean loss of 10.6%, participants who kept taking it lost a further 7.9% by week 68, while those switched to placebo regained 6.9%.

In the STEP 1 extension study (327 participants), one year after stopping semaglutide 2.4 mg and the lifestyle program, participants had regained about two-thirds of the weight they had lost — net loss fell from 17.3% at week 68 to 5.6% at week 120 — and cardiometabolic improvements largely reverted.

None of these figures is a prediction for you: they are trial means at the 2.4 mg injection and 25 mg tablet doses, measured at 64 to 68 weeks with structured lifestyle counseling, and results were smaller in people with type 2 diabetes.

The most common side effects in Wegovy's weight trials are gastrointestinal; the rates below are from the 2.4 mg injection trials, which followed 2,116 adults on Wegovy and 1,261 on placebo.

• Nausea: 44% versus 16% on placebo
• Diarrhea: 30% versus 16%
• Vomiting: 24% versus 6%
• Constipation: 24% versus 11%
• Abdominal pain: 20% versus 10%
• Headache: 14% versus 10%
• Fatigue: 11% versus 5%
• Hair loss: 3% versus 1%

Across the adult weight trials, 73% of patients on Wegovy injection reported gastrointestinal side effects versus 47% on placebo, and they were most often reported during dose escalation — the reason the label titrates slowly.

In STEP 1, nausea and diarrhea were typically transient and mild-to-moderate and subsided with time.

Some patients stop the drug over side effects: in the weight trials, 6.8% of patients on Wegovy 2.4 mg versus 3.2% on placebo permanently stopped because of adverse reactions, most commonly nausea, vomiting and diarrhea.

The label also names less common risks: gallstones were reported by 1.6% of Wegovy injection patients versus 0.7% on placebo, acute pancreatitis was confirmed in 4 Wegovy-treated patients (0.2 cases per 100 patient-years) versus 1 on placebo, and other warnings cover acute kidney injury from dehydration, severe gastrointestinal reactions, hypersensitivity, diabetic retinopathy complications, an increase in heart rate, and pulmonary aspiration under anesthesia.

Wegovy is priced per month of supply, and its manufacturer publishes cash prices for people paying without insurance; the figures below are Novo Nordisk's own self-pay prices, read from its NovoCare pages on October 16, 2026, and the company says it may change or cancel them at any time.

New patients: Novo's offer prices the first two monthly fills of the 0.25 mg and 0.5 mg starter doses at $199 per month through December 31, 2026, then $349 per month.

For people with commercial insurance, Novo's savings offer says patients may pay as little as $25 per month, with a maximum savings of $100 per month; coverage of weight-management medications varies by plan.

A med spa or clinic program is priced separately from the medication, and we could not confirm a national figure for what programs charge on top of it — ask each clinic what its monthly fee includes before you pay: the medication itself, prescriber or nursing visits, lab work, a membership.

FDA lists deep discounts that seem too good to be true among its GLP-1 red flags, which is worth remembering when a program's price looks far below the manufacturer's own.

Semaglutide is prescription-only: it takes a valid prescription from a licensed prescriber, and FDA tells patients to fill that prescription at a state-licensed pharmacy.

Who may prescribe is not one national rule: for nurse practitioners, whether they may prescribe independently depends on the state.

AANP, the nurse practitioners' professional association, classifies states as Full Practice (NPs may evaluate, diagnose and prescribe under the board of nursing alone), Reduced Practice (a career-long collaborative agreement is required for at least one element of practice) or Restricted Practice (career-long supervision, delegation or team management is required).

What any legitimate program must do is fixed by the prescription requirement: a licensed prescriber evaluates you, writes the prescription if you qualify, and the prescription is filled at a state-licensed pharmacy.

The Wegovy label's dosing also tells you what a first prescription should look like: it starts low — 0.25 mg weekly for the injection — and escalates on the label's schedule, reaching the recommended 2.4 mg maintenance dose at week 17.

Because gastrointestinal side effects are most often reported during dose escalation, it is fair to ask any program who you contact when a dose does not agree with you and how a prescription gets adjusted.

What we could not confirm is what any specific program's first visit includes: no verified source describes a standard, so ask the clinic to spell out its visit schedule, lab work and fees in writing.

When you compare programs, the first thing to verify is the prescription chain: a licensed prescriber should evaluate you, and the medication should come from a state-licensed pharmacy.

FDA's red flags for GLP-1 sellers include:

• claims that a compounded drug is the same as an FDA-approved drug
• deep discounts that seem too good to be true
• no medical screening, and no prescription by a licensed doctor
• no doctor available for questions
• label spelling errors or wrong pharmacy addresses
• a pharmacy name you suspect is fraudulent

FDA is also aware of fraudulent compounded semaglutide and tirzepatide whose labels name pharmacies that do not exist, or licensed pharmacies that did not actually make the product.

Before you pay anything, you can check a prescriber's license through your state's licensing board and ask the clinic where its pharmacy is licensed.

If a program is vague about who prescribes, where the medication comes from or what the fee covers, those are reasons to keep looking.